SUVEN LIFE SCIENCES LTD.

Suven Life Sciences Ltd has announced the closure of its trading window for designated persons and their immediate relatives, effective October 1, 2026. This closure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's internal code of conduct. The window will remain shut until 48 hours after the declaration of the unaudited financial results for the quarter and half-year ended September 30, 2026. All designated individuals are advised against trading in the company's securities during this period. The date for the board meeting to approve these financial results will be communicated separately.

Suven Life Sciences announced the completion of patient enrollment in its global Phase-3 clinical study for Masupirdine (SUVN-502), a potential treatment for agitation associated with Alzheimer's Dementia (AAD). The study, conducted across the USA and Europe, randomized 424 patients, exceeding the initial target of 375. The Last Patient Last Visit (LPLV) is anticipated by December 2026, with database lock expected by March 2027 and topline results by May 2027. Masupirdine is a selective 5-HT6 receptor antagonist aiming to offer a differentiated treatment option compared to existing sedatives or antipsychotics, which have significant limitations in this vulnerable patient population. The company's management expressed optimism about the study's completion and the potential of Masupirdine to address a significant unmet need.

Suven Life Sciences Ltd has submitted its Monitoring Agency (MA) Report for the quarter ended June 30, 2026, issued by CRISIL Ratings Limited. This report, prepared in accordance with SEBI regulations, details the utilization of proceeds from the company's Preferential Issue. The issue size was ₹85,764.02 lakhs, comprising convertible warrants. The report confirms no deviation from the stated objects of the issue. CRISIL Ratings Limited, acting as the Monitoring Agency, has provided an objective view based on information from the issuer and reliable sources, clarifying that they do not perform audits or independent verification.

Suven Life Sciences Ltd announced its un-audited financial results for the quarter ended June 30, 2026. The Board of Directors approved the standalone and consolidated results along with the limited review reports from the statutory auditors. The meeting to approve these results was held on August 6, 2026. The company also provided a link for patent updates.

Consolidated net loss for the quarter ended 30 June 2026 (Q1 FY27) widened to ₹127.61 Cr, up 147.7% YoY from ₹51.52 Cr and 179.9% QoQ from ₹45.60 Cr, per un-audited results approved by the Board on 6 August 2026. Diluted EPS was -₹4.84 versus -₹2.36 a year ago. Revenue from operations was ₹3.57 Cr against ₹1.87 Cr YoY — traditional margin metrics (NPM/OPM) aren't meaningful here since Suven remains a pre-revenue, clinical-stage biopharmaceutical rather than a commercial-revenue business. Consolidated R&D and operating expenses rose to ₹123.83 Cr from ₹41.49 Cr YoY (+198%) and ₹42.33 Cr QoQ (+193%), the direct driver of the wider loss; standalone R&D was a comparatively modest ₹12.76 Cr, confirming nearly all of the increase sits in the wholly-owned US subsidiary, Suven Neurosciences Inc. The auditor's limited-review report separately discloses the subsidiary posted a ₹111.49 Cr net loss (total comprehensive loss ₹111.47 Cr) on nil revenue for the quarter — consistent with the roughly ₹111.5 Cr gap between standalone (-₹16.12 Cr) and consolidated (-₹127.61 Cr) loss. There was no tax and no exceptional item in either the current or comparison periods, so no adjusted-vs-reported split is needed here. Other income was ₹7.52 Cr, 68% of the ₹11.09 Cr total income, likely interest earned on the ₹857.64 Cr raised via convertible warrants, of which ₹448.14 Cr remained un-utilised as of 30 June 2026 (note 6). No management guidance or prior concall commentary is on record, and a web search turned up no brokerage previews or consensus estimates for this quarter — Suven carries no visible analyst coverage tracking its quarterly P&L, consistent with its status as a pre-commercial, trial-stage name; vs-street and vs-guidance are both unknown. Management's own news release does not address the loss at all, framing the quarter entirely around pipeline milestones instead. The spend is tied to three active programs: SUVN-502 (Masupirdine) for Alzheimer's-related agitation hit 95% enrolment in its global Phase 3 trial, with enrolment completion targeted for September 2026 and a potential database lock/results readout in Q2 CY2027; SUVN-G3031 (Samelisant) started a Phase 3 trial for narcolepsy-related excessive daytime sleepiness in April 2026; and SUVN-911 (Ropanicant) completed Phase 2b in major depressive disorder. With ₹448.14 Cr of warrant proceeds still unutilised, near-term loss and cash-burn trends will likely keep tracking the pace of these trials rather than any commercial revenue ramp.

Suven Life Sciences Limited has announced that its Board of Directors will convene on August 6, 2026. The primary agenda item for this meeting is to consider and approve the Un-Audited Financial Results of the company, both on a standalone and consolidated basis, for the quarter that ended on June 30, 2026. Additionally, the board will discuss related matters. The company has also informed that the trading window for its securities, which was closed from July 1, 2026, will remain shut for 48 hours post the declaration of these financial results, in compliance with the SEBI (LODR) Regulations, 2015 and the company's insider trading code.

Suven Life Sciences Limited has issued a letter to shareholders regarding its Annual Report for the Financial Year ended March 31, 2026. The report has been emailed to shareholders with registered email addresses. For those without registered emails, the complete Annual Report can be accessed via a web-link and QR code on the company's website. Shareholders are reminded of the SEBI mandate to update PAN, KYC, and nomination details with their Depository Participant/RTA to ensure uninterrupted payments like dividends. A dedicated Senior Citizens Investor Cell is also available for assistance.

Suven Life Sciences Limited has submitted its Business Responsibility and Sustainability Report (BRSR) for the Financial Year 2025-26, in compliance with SEBI (LODR) Regulations, 2015. The report, formulated according to SEBI Guidelines, aims to enhance transparency by detailing the company's value generation through contributions to a sustainable economy. It emphasizes Suven's commitment to sustainable development and stakeholder value. The filing includes general entity disclosures, product/service details (100% from Scientific Research & Development), operational information, and employee data. The company operates on a standalone reporting basis and received 'Limited Assurance' from J Sundharesan & Associates.

Suven Life Sciences Ltd has announced its 37th Annual General Meeting (AGM) to be held on Tuesday, August 25, 2026, at 11:30 a.m. IST via Video Conference (VC) / Other Audio Visual Means (OAVM). The AGM will transact ordinary business including the adoption of audited standalone and consolidated financial statements for the financial year ended March 31, 2026, and the re-appointment of Prof. Seyed E Hasnain as a Director. Special business includes approving a related party transaction for the appointment of Dr. Madhavi Jasti to an office or place of profit in overseas wholly-owned subsidiaries, with an initial annual remuneration of USD 400,000, potentially revised up to USD 1,000,000. Remote e-voting is available from August 21 to August 24, 2026.

Suven Life Sciences Ltd has announced its 37th Annual General Meeting (AGM) to be held on August 25, 2026, via Video Conference. The company also released its Annual Report for the Financial Year 2025-26. Key highlights from the report indicate insignificant revenue growth (₹21.05 Cr in FY26 vs ₹17.55 Cr in FY25), increased R&D investment (₹291.62 Cr in FY26 vs ₹172.43 Cr in FY25), and a widened net loss (₹276.34 Cr in FY26 vs ₹160.75 Cr in FY25). The report details the company's progress on its clinical-stage assets, including Masupirdine (Phase 3 for Alzheimer's), Samelisant (Phase 3 for EDS), and Ropanicant (Phase 2b completed for MDD). The company emphasizes its long-term strategy in CNS research, backed by a significant patent portfolio and a dedicated research team.